EXEL Exelixis Inc

$EXEL this request doesn’t affect the approval of the drug it generally speaking it just extends the breath of the label for the drug It’s not a negative it’s actually a positive it’s gonna lead to an approval with extending the breath of the label based upon side effects

EXEL Stock Slides After FDA Adds Three Months To Cancer Drug Review — William Blair Sees More Swings In Near Term $EXEL $IJH $VTI https://stocktwits.com/news/equity/markets/exel-stock-slides-after-fda-adds-three-months-to-cancer-drug-review-william-blair-sees-more-swings-in-near-term/cZtXM0eRBbg

$EXEL Exelixis says FDA extends review period for zanzalintinib NDA by three months Exelixis announced that on September 10, the U.S. Food and Drug Administration notified Exelixis that it had extended the review period for Exelixis' new drug application for zanzalintinib, in combination with atezolizumab, for the treatment of patients with metastatic colorectal cancer by three months. In response to an FDA information request, Exelixis had submitted updated safety and efficacy data, which the FDA has deemed a major amendment. The updated Prescription Drug User Fee Act action date is March 3, 2027.

$EXEL Google AI Redpone to: "Tiawsn, Excelixis citizens petitoon" The U.S. Food and Drug Administration (FDA) completely rejected a Citizen Petition filed by US-based pharmaceutical company Exelixis against the Taiwanese pharmaceutical firm, Handa Pharmaceuticals. [1, 2] Concurrently, on September 3, 2026, Handa's novel formulation cancer drug, HND-039 (Omcazio), received final FDA approval. [1] Background of the Dispute The Petition: In April 2026, Exelixis (the originator of the blockbuster cancer drug Cabometyx) filed a 505(q) Citizen Petition requesting that the FDA refuse or delay approval for Handa's drug. Exelixis claimed Handa's product required more clinical data regarding safety and effectiveness. [1, 2] The Patent Lawsuit: Alongside the FDA petition, Exelixis filed patent infringement lawsuits to block Handa's copycat drug. However, on August 27, 2026, Exelixis voluntarily dismissed its patent lawsuit against Handa. [1, 2]

I was just asked about $EXEL in my Live Trading Room and, yes, it's a beauty. My response: Beauty! Strong uptrend with base forming. BGS rule applies today but I've got it on my greens list. Likely will coil up a bit. But if not, we can join. Cycles and MACD in good spots